NASDAQ: DMII
Drugs Made In America Acquisition II Corp Earnings Dates, Reports, Calls

Drugs Made In America Acquisition II earnings were $4.2M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest DMII earnings report on Dec 31, 2025 announced Q4 2025 earnings of $4.3M, down 9,482.1% from last quarter.

DMII earnings history

Current Revenue
$0.0
Current Earnings
$4.2M
Current Profit Margin
0%

DMII Return on Equity

Current Company
-46.8%
Current Industry
113.3%
Current Market
28.9%

DMII Return on Assets

Current Company
1.7%
Current Industry
1.3%

Be the first to know when DMII announces earnings.

DMII Return on Capital Employed

Current Company
0.83%
Current Industry
1.4%

DMII vs Shell Company Stocks

TickerEBITDAEarningsY/Y EarningsEPS
DMII$4.19M$4.19MN/A$0.16
UMAC-$19.09M-$19.19MN/A-$0.74
BCSS$4.26M$4.26MN/A$0.17
EVAC$8.92M$8.92MN/A$0.26
WSTNN/AN/AN/AN/A

Drugs Made In America Acquisition II Earnings Reports & History FAQ

What were Drugs Made In America Acquisition II's earnings last quarter?

Drugs Made In America Acquisition II (NASDAQ: DMII) reported Q4 2025 earnings per share (EPS) of $0.17, up 1,800% year over year. Total DMII earnings for the quarter were $4.33 million. In the same quarter last year, Drugs Made In America Acquisition II's earnings per share (EPS) was -$0.01.

If you're new to stock investing, here's how to buy Drugs Made In America Acquisition II stock.

Is Drugs Made In America Acquisition II profitable or losing money?

As of the last Drugs Made In America Acquisition II earnings report, Drugs Made In America Acquisition II is currently profitable. Drugs Made In America Acquisition II's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $4.19 million, a N/A decrease year over year.

What was DMII's earnings growth in the past year?

As of Drugs Made In America Acquisition II's earnings date in Q2 2026, Drugs Made In America Acquisition II's earnings has grown year over year. DMII earnings in the past year totalled $4.19 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.